Compare Novavax Inc (NVAX) vs Tesla, Inc. (TSLA) Price & Performance

Novavax (NVAX) trades at $8.14, up 2.39% today, with a bearish technical signal despite recent earnings beats. The company reported a net loss of $53 million in Q2 2026 but raised its full-year revenue outlook, driven by licensing milestones from its Sanofi partnership. Valuation ratios like P/E of 3.14 and EV/EBITDA of 1.72 appear low, yet negative profitability margins and cash flow challenges persist.

The outlook is mixed: analyst consensus is 74% buy with potential from partnerships, but risks include sustained losses, high debt, and competitive vaccine market pressure. Investors should weigh the low valuation against fundamental weaknesses and monitor execution on cost reductions and pipeline progress for upside catalysts.

Tesla (TSLA) trades at $339.96, up 2.18% today, but faces a bearish technical signal with support near $320 and resistance at $334. Recent earnings showed a Q2 2026 miss, with revenue declining to $94.83B in 2025 and net income margin compressing to 3.67%. Valuation ratios remain elevated, with a P/E of 303.25, while news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch.

The outlook is mixed: analyst consensus targets $393.87 with 40.74% buy ratings, but high valuation and competitive pressures pose risks. Growth hinges on AI and energy initiatives offsetting auto slowdowns, with net cash flow turning positive in 2025. Investors must weigh innovation potential against execution risks and margin pressures.